Portage Biotech

71 articles with Portage Biotech

• Portage Biotech Announces Appointment Of New Director

  8/5/2016

• FDA Clears Biohaven's Investigational New Drug Application For BHV-4157 And Portage Biotech To Hold Investor Conference Call To Provide Business Update

  7/5/2016

• Portage Biotech Announces Orphan Drug Designation Request Granted To Biohaven For BHV-4157

  5/25/2016

• Portage Biotech Announces The Appointment Of Chief Commercial Officer At Biohaven

  4/27/2016

• Portage Biotech Announcing Results Of Its Annual Shareholder Meeting And Other Corporate Matters

  4/7/2016

• Portage Biotech's Further Investment In Biohaven

  3/23/2016

• Portage Biotech Announces Proposed Private Placement

  3/11/2016

• Portage Biotech's Biohaven Orphan Drug Designation Request Granted For The Treatment Of Spinocerebellar Ataxia

  3/4/2016

• Portage Biotech's Biohaven Announces Positive Results From Phase 1 Study With BHV-0223

  2/25/2016

• Portage Biotech's Biohaven Announces Expedited Development Path For BHV-0223 Following Successful Pre-IND Interaction With FDA

  2/25/2016

• Portage Biotech Provides Updates On Portage Pharma

  1/25/2016

• Portage Biotech Issues Letter To Shareholders

  1/15/2016

• Mr. James Mellon And Dr. Gregory Bailey ("Offerors") Announce Additional Shares In Portage Biotech

  12/15/2015

• Portage Biotech's Biohaven Announces Phase 1 Pharmacokinetic Study Meets Study Objectives And Supports Advancing BHV-0223 And Also Appoints A CEO

  11/20/2015

• Portage Biotech's Biohaven Completes Multiple Dose Phase Of Pharmacokinetic Trial With BHV-0223

  10/6/2015

• Portage Biotech's Biohaven Completes Single Dose Phase Of Pharmacokinetic Trial With BHV-0223

  9/22/2015

• Portage Biotech Issues Letter To Shareholders

  9/10/2015

• Portage Biotech's PPL Will Advance Its Lead Candidate PPL-003 To An IND For Dry Eye Disease And Uveitis

  8/31/2015

• Portage Biotech's Biohaven Doses First Human Subject In Phase 1 Trial With Lead Drug Candidate BHV-0223

  8/27/2015

• Portage Biotech's Biohaven's Lead Drug Candidate Clears FDA Investigational New Drug Application (IND) Review And Clinical Studies To Begin

  8/24/2015